RxDoctor Payments Data

Brian Hyman, MD

Neurology · State College, PANPI 1467415315

Payments from drug & device makers

$7,209in general payments, 2019–2025

Across 558 payments — averaging $12.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$1K
  • Novartis$287
  • Acadia Pharmaceuticals Inc$280
  • Lundbeck LLC$244
  • Lilly USA, LLC$233
  • plus $3K from 45 others

What the payments were for

  • Food & beverage$7,195100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,209 in reported general payments places this provider in the 70th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$63,288
Medicare patients
332
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab27$242,224
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$135,499
IngrezzaValbenazine Tosylate15$115,860
Nurtec OdtRimegepant Sulfate58$91,999
Emgality PenGalcanezumab-Gnlm73$52,292
RexultiBrexpiprazole13$40,488
KeppraLevetiracetam31$37,448
RytaryCarbidopa/Levodopa53$31,352
QuliptaAtogepant29$30,467
BriviactBrivaracetam13$19,520
Tetrabenazine13$18,422
Aimovig AutoinjectorErenumab-Aooe25$17,800
Rufinamide13$17,770
Carbidopa-LevodopaCarbidopa/Levodopa400$15,165
TopamaxTopiramate13$14,691

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$70$135,49913 claims
Neurocrine Biosciences, Inc.Ingrezza$127$115,86015 claims
PfizerNurtec Odt$48$91,99958 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$162$34,81598 claims
AbbVieQulipta$1,412$30,46729 claims
UCB, Inc.Briviact$118$19,52013 claims
Upsher-smith Laboratories LLCTopiramate$75$3,445208 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 941 neurology providers in Pennsylvania.

Other neurology in State College

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →